they admit it!!, page-6

"MBP isnt the only stock making a loss champ on the ASX!!
lots of other bio's and other sector stocks are at a loss at either R & D stages or drilling etc etc...

yet some continue to go up in price coz of speculation or the potential of the stock! simple really"

Agreed, of course. However, MBP has been the subject of a lot of ramping, not least of which was their own, paid-for "valuation" of over $2 per share by Cohen in the USA. It wasn't until later that MBP had to admit that they paid for this "newsletter". That, plus the very dubious potential of the weight-loss drug, makes it far more than a "normal" speculative share in my book.

The weight-loss drug will surely turn into a fizzer, as have all others before it, and their best hope of turning one of their developments into something that may be a commercial success is their analgesic. But that is far too early in development to hazard even a wild guess on its chances yet.

Of course I'm well aware of speccie plays in the market - I hold quite a few as we speak - but I rate their chances of success at better than even money. In most cases, MUCH better than even money.

As I posted, MBP is fine for volatility traders, purely as a vehicle for making a quick profit, but for the longer-term investor, I can see nothing but grief.

Once again - just my opinion as usual :)